The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.
In many cases, the drug required physicians to request prior authorization.
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push